



Name	Su Jong Yu	
Current Position	Clinical Professor	
Country	Republic of Korea	
Major Field	Hepatology	

Educational Background

1. Doctor of Medicine, College of Medicine, Dept. of Medicine, Seoul National University (March 1, 1997 – February 26, 2001)
2. Master of Science in Medicine, Graduate School, Seoul National University (March 1, 2004 – February 24, 2006)
3. Doctor of Philosophy in Medical Science, Graduate School, Seoul National University (March 1, 2010 – February 24, 2012)

Professional Experience

- 1) Clinical Professor, Department of Internal Medicine & Liver Research Institute, SNU College of Medicine (2011.03 ~ Present)
- 2) Visiting Scientist, NCI, NIH (Bethesda, MD, USA) (2016 ~ 2018)
- 3) Seoul National University College of Medicine, Doctor of Medicine (2010 ~ 2012)
- 4) Seoul National University College of Medicine, Master of Medicine (2004 ~ 2006)
- 5) Seoul National University College of Medicine, Bachelor of Medicine (1997 ~ 2001)

Other Experience and Professional Memberships

- 1) Academy Affairs Director, KLCA (2022.07 ~ Present)
- 2) Associate Editor, Gut and Liver (2021.12 ~ Present)
- 3) Vice Secretary General & Director of the Liaison Committee, KASL (2019.12 ~ 2021.12)

Main Scientific Publications

1. Cho EJ, Chung GE, Yoo JJ, Cho Y, Shin DW, Kim YJ, Yoon JH, Han K, **Yu SJ**. The association between alcohol consumption and the risk of hepatocellular carcinoma according to glycemic

-
- status in Korea: A nationwide population-based study. *PLoS Med.* 2023 Jun 12;20(6):e1004244. doi: 10.1371/journal.pmed.1004244. eCollection 2023 Jun.
2. Chung GE, Cho EJ, Kim MJ, Yoo JJ, Cho Y, Lee KN, Han K, Kim YJ, Yoon JH, Shin DW, **Yu SJ**. Association between the fatty liver index and the risk of fracture among individuals over the age of 50 years: a nationwide population-based study. *Front Endocrinol (Lausanne)*. 2023 May 16;14:1156996. doi: 10.3389/fendo.2023.1156996. eCollection 2023.
 3. Cho EJ, Jeong SM, Chung GE, Yoo JJ, Cho Y, Lee KN, Shin DW, Kim YJ, Yoon JH, Han K, **Yu SJ**. Gamma-glutamyl transferase and risk of all-cause and disease-specific mortality: a nationwide cohort study. *Sci Rep.* 2023 Jan 31;13(1):1751. doi: 10.1038/s41598-022-25970-0.
 4. Chung GE, **Yu SJ**, Yoo JJ, Cho Y, Lee KN, Shin DW, Kim D, Kim YJ, Yoon JH, Han K, Cho EJ. Lean or diabetic subtypes predict increased all-cause and disease-specific mortality in metabolic-associated fatty liver disease. *BMC Med.* 2023 Jan 4;21(1):4. doi: 10.1186/s12916-022-02716-3.
 5. Chung GE, Jeong SM, Cho EJ, Yoon JW, Yoo JJ, Cho Y, Lee KN, Shin DW, Kim YJ, Yoon JH, Han K, **Yu SJ**. The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study. *Cardiovasc Diabetol.* 2022 Dec 6;21(1):273.
 6. Cho EJ, **Yu SJ**, Lee YB, Lee JH, Kim YJ, Yoon JH. Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. *Diagnostics (Basel)*. 2022 May 7;12(5):1170.
 7. Chung GE, Jeong SM, Cho EJ, Yoo JJ, Cho Y, Lee KN, Shin DW, Kim YJ, Yoon JH, Han K, **Yu SJ**. Association of fatty liver index with all-cause and disease-specific mortality: A nationwide cohort study. *Metabolism.* 2022 Aug;133:155222.
 8. Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, Han K, Jeong SM, Yoon KW, Shin DW, **Yu SJ**, Kim YJ, Yoon JH. Young adults with nonalcoholic fatty liver disease, defined using the fatty liver index, can be at increased risk of myocardial infarction or stroke. *Diabetes Obes Metab.* 2022 Mar;24(3):465-472.
 9. Cho Y, Cho EJ, Yoo JJ, Chang Y, Chung GE, Choi IY, Park SH, Han K, Kim YJ, Yoon JH, Shin DW, **Yu SJ**. The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study. *Front Oncol.* 2022 May 4;12:863352.
 10. Yoo JJ, Cho EJ, Chung GE, Chang Y, Cho Y, Park SH, Jeong SM, Kim BY, Shin DW, Kim YJ, Yoon JH, Han K, **Yu SJ**. Nonalcoholic Fatty Liver Disease Is a Precursor of New-Onset Metabolic Syndrome in Metabolically Healthy Young Adults. *J Clin Med.* 2022 Feb 11;11(4):935.
-

-
11. Chung GE, Cho EJ, Yoon JW, Yoo JJ, Chang Y, Cho Y, Park SH, Han K, Shin DW, **Yu SJ**. Nonalcoholic fatty liver disease increases the risk of diabetes in young adults: A nationwide population-based study in Korea. *Metabolism*. 2021 Oct;123:154866.
 12. Chung GE, Chang Y, Cho Y, Cho EJ, Yoo JJ, Park SH, Han K, Shin DW, **Yu SJ**, Kim YJ, Yoon JH. The Change in Metabolic Syndrome Status and the Risk of Nonviral Liver Cirrhosis. *Biomedicines*. 2021 Dec 20;9(12):1948.
 13. Chung GE, Cho EJ, Yoo JJ, Chang Y, Cho Y, Park SH, Shin DW, Han K, **Yu SJ**. Nonalcoholic fatty liver disease is associated with the development of obstructive sleep apnea. *Sci Rep*. 2021 Jun 29;11(1):13473.
 14. Cho Y, Cho EJ, Yoo JJ, Chang Y, Chung GE, Jeong SM, Park SH, Han K, Shin DW, **Yu SJ**. Association between Lipid Profiles and the Incidence of Hepatocellular Carcinoma: A Nationwide Population-Based Study. *Cancers (Basel)*. 2021 Mar 30;13(7):1599.
 15. Yoo JJ, Cho EJ, Han K, Heo SS, Kim BY, Shin DW, **Yu SJ**. Glucose Variability and Risk of Hepatocellular Carcinoma in Patients with Diabetes: A Nationwide Population-Based Study. *Cancer Epidemiol Biomarkers Prev*. 2021 May;30(5):974-981.
 16. Chang Y, Yoo JJ, Cho EJ, Han K, Kim D, Kim BY, Chung GE, Cho Y, Shin DW, **Yu SJ**. Weight fluctuation and risk of hepatocellular carcinoma: a nationwide population-based 8-million-subject study. *Hepatol Int*. 2021 Apr;15(2):482-492.
 17. Cho EJ, Han K, Lee SP, Shin DW, **Yu SJ**. Liver enzyme variability and risk of heart disease and mortality: A nationwide population-based study. *Liver Int*. 2020 Jun;40(6):1292-1302.
 18. Yoo JJ, **Yu SJ**, Lee B, Cho EJ, Lee JH, Kim SG, Kim YJ, Kim YS, Yoon JH. Appraisal of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma Classified as Barcelona Clinic Liver Cancer Stage B. *Gut Liver*. 2020 May 15;14(3):377-386.
 19. Yoo JJ, **Yu SJ**, Na J, Kim K, Cho YY, Lee YB, Cho EJ, Lee JH, Kim YJ, Youn H, Yoon JH. Hexokinase-II Inhibition Synergistically Augments the Anti-tumor Efficacy of Sorafenib in Hepatocellular Carcinoma. *Int J Mol Sci*. 2019 Mar 14;20(6).
 20. Cho EJ, **Yu SJ**, Kim K, Cho H, Cho YY, Lee YB, Lee JH, Kim YJ, Youn H, Yoon JH. Carbonic anhydrase-IX inhibition enhances the efficacy of hexokinase II inhibitor for hepatocellular carcinoma in a murine model. *J Bioenerg Biomembr*. 2019 Apr;51(2):121-129.
 21. **Yu SJ**, Ma C, Heinrich B, Brown ZJ, Sandhu M, Zhang Q, Fu Q, Agdashian D, Rosato U, Korangy F, Greten TF. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. *J Hepatol*. 2019 Mar;70(3):449-457
 22. Cho EJ, **Yu SJ**, Kwon SY, Kim JH, Kim DY, Kim W, Lee JS, Lee JW, Lee YJ, Chae HB, Yoon
-

- JH. Concomitant food intake does not affect the efficacy of entecavir in chronic hepatitis B patients with virological response: a randomized, multicenter, noninferiority trial. *Drug Des Devel Ther.* 2018 Nov 2;12:3767-3774.
23. Cho YY, **Yu SJ**, Yoo JJ, Lee M, Lee DH, Cho Y, Yoon KW, Cho EJ, Lee JH, Kim YJ, Yoon JH. The Model to Estimate Survival in Ambulatory Hepatocellular Carcinoma Patients Aids in the Decision for TACE Retreatment. *J Clin Gastroenterol.* 2020 Apr;54(4):370-377.
24. Choi WM, **Yu SJ**, Ahn H, Cho H, Cho YY, Lee M, Yoo JJ, Cho Y, Lee DH, Cho EJ, Lee JH, Kim YJ, Yoon JH. A model to estimate survival in ambulatory patients with hepatocellular carcinoma: Can it predict the natural course of hepatocellular carcinoma? *Dig Liver Dis.* 2017 Nov;49(11):1273-1279.
25. **Yu SJ**, Kwon JH, Kim W, Yoon JH, Lee JM, Lee JY, Cho EJ, Lee JH, Kim HY, Jung YJ, Kim YJ. Initial Alpha-Fetoprotein Response Predicts Prognosis in Hepatitis B-related Solitary HCC Patients After Radiofrequency Ablation. *J Clin Gastroenterol.* 2018 Mar;52(3):e18-e26.
26. Kim H, **Yu SJ**, Yeo I, Cho YY, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Lee S, Jun J, Park T, Yoon JH, Kim Y. Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS). *Mol Cell Proteomics.* 2017 Jul;16(7):1312-1323.
27. Won JK, **Yu SJ**, Hwang CY, Cho SH, Park SM, Kim K, Choi WM, Cho H, Cho EJ, Lee JH, Lee KB, Kim YJ, Suh KS, Jang JJ, Kim CY, Yoon JH, Cho KH. Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma. *Hepatology.* 2017 Sep;66(3):855-868.
28. **Yu SJ**, Kim H, Min H, Sohn A, Cho YY, Yoo JJ, Lee DH, Cho EJ, Lee JH, Gim J, Park T, Kim YJ, Kim CY, Yoon JH, Kim Y. Targeted Proteomics Predicts a Sustained Complete-Response after Transarterial Chemoembolization and Clinical Outcomes in Patients with Hepatocellular Carcinoma: A Prospective Cohort Study. *J Proteome Res.* 2017 Mar 3;16(3):1239-1248.
29. **Yu SJ**, Yoon JH, Kim W, Lee JM, Lee YB, Cho Y, Lee DH, Lee M, Yoo JJ, Cho EJ, Lee JH, Kim YJ, Kim CY. Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis. *Korean J Intern Med.* 2017 Mar;32(2):261-268.
30. Cho Y, Sinn DH, **Yu SJ**, Gwak GY, Kim JH, Yoo YJ, Jun DW, Kim TY, Lee HY, Cho EJ, Lee JH, Kim YJ, Yoon JH. Survival Analysis of Single Large (>5 cm) Hepatocellular Carcinoma Patients: BCLC A versus B. *PLoS One.* 2016 Nov 15;11(11):e0165722.
31. **Yu SJ**, Yoon JH, Lee JM, Lee JY, Kim SH, Cho YY, Yoo JJ, Lee M, Lee DH, Cho Y, Cho EJ, Lee JH, Kim YJ, Kim CY. Percutaneous ethanol injection therapy is comparable to radiofrequency ablation in hepatocellular carcinoma smaller than 1.5cm: A matched case-control comparative analysis. *Medicine (Baltimore).* 2016 Aug;95(35):e4551.
32. **Yu SJ**, Kim W, Kim D, Yoon JH, Lee K, Kim JH, Cho EJ, Lee JH, Kim HY, Kim YJ, Kim CY. Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

-
- Medicine (Baltimore). 2015 Dec;94(48):e2159.
33. **Yu SJ**, Kim YJ. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein. 2015 Jun 18;7(11):1553-61. doi: 10.4254/wjh.v7.i11.1553.
34. Cho Y, **Yu SJ**, Cho EJ, Lee JH, Kim TM, Heo DS, Kim YJ, Yoon JH. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma. J Med Virol. 2016 Jun;88(6):1010-7.
35. **Yu SJ**, Bae S, Kang JS, Yoon JH, Cho EJ, Lee JH, Kim YJ, Lee WJ, Kim CY, Lee HS. Hepatoprotective effect of vitamin C on lithocholic acid-induced cholestatic liver injury in Gulo(-/-) mice. Eur J Pharmacol. 2015 Sep 5;762:247-55.
36. Kwak MS, **Yu SJ**, Yoon JH, Lee SH, Lee SM, Lee JH, Kim YJ, Lee HS, Kim CY. Synergistic anti-tumor efficacy of doxorubicin and flavopiridol in an in vivo hepatocellular carcinoma model. J Cancer Res Clin Oncol. 2015 Nov;141(11):2037-45.
37. Hwang SY, **Yu SJ**, Lee JH, Kim JS, Yoon JW, Kim YJ, Yoon JH, Kim EC, Lee HS. Spontaneous fungal peritonitis: a severe complication in patients with advanced liver cirrhosis. Eur J Clin Microbiol Infect Dis. Eur J Clin Microbiol Infect Dis. 2014 Feb;33(2):259-64.
38. **Yu SJ**, Kim JW, Lee JH, Yoon JH, Lee HS, Cheong JY, Cho SW, Shin HD, Kim YJ. Association of a microRNA-323b polymorphism with the persistence of hepatitis B virus infection by the enhancement of viral replication. J Viral Hepat. 2014 Dec;21(12):853-859.
39. **Yu SJ**, Won JK, Ryu HS, Choi WM, Cho H, Cho EJ, Lee JH, Kim YJ, Suh KS, Jang JJ, Kim CY, Lee HS, Yoon JH, Cho KH. A novel prognostic factor for hepatocellular carcinoma: protein disulfide isomerase. Korean J Intern Med. 2014 Sep;29(5):580-587.
40. **Yu SJ**, Lee JH, Jang ES, Cho EJ, Kwak MS, Yoon JH, Lee HS, Kim CY, Kim YJ. Hepatocellular Carcinoma: High Hepatitis B Viral Load and Mortality in Patients Treated with Transarterial Chemoembolization. Radiology. 2013 May;267(2):638-47.
41. **Yu SJ**, Yoon JH, Yang JI, Cho EJ, Kwak MS, Jang ES, Lee JH, Kim YJ, Lee HS, Kim CY. Enhancement of hexokinase II inhibitor-induced apoptosis in hepatocellular carcinoma cells via augmenting ER stress and anti-angiogenesis by protein disulfide isomerase inhibition. J Bioenerg Biomembr. 2012 Feb;44(1):101-15.
42. Kim JH, **Yu SJ**, Park BL, Cheong HS, Pasaje CF, Bae JS, Lee HS, Shin HD, Kim YJ. TGFBR3 polymorphisms and its haplotypes associated with chronic hepatitis B virus infection and age of hepatocellular carcinoma occurrence. Dig Dis. 2011;29(3):278-83.
43. **Yu SJ**, Yoon JH, Lee JH, Myung SJ, Jang ES, Kwak MS, Cho EJ, Jang JJ, Kim YJ, Lee HS. The inhibition of hypoxia-inducible carbonic anhydrase-IX enhances hexokinase II inhibitor-induced hepatocellular carcinoma cell apoptosis. Acta Pharmacol Sin. 2011;32(7):912-920.
-